KH-CB19

Research use only, not for human use.

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1).

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1), displays almost 100-fold selectivity against the CLK3 isoform; effectively suppresses phosphorylation of SR (serine/arginine) proteins SRp75 and SRp55 in cells; significantly reduces the basal expression of flTF as well as asHTF, also lowers TNF-α-induced expression of both TF mRNA splice variants to baseline in HMEC-1 cells.

KH-CB19 (10 μM; 1 h) shows CLK inhibition on SR protein phosphorylation in human microvascular endothelial cells.KH-CB19 (50?μM; 6 h) inhibits the disruption by CLK4 in A549?cells. Western Blot Analysis Cell Line:Human microvascular endothelial cells (HMEC-1) Concentration:10 μM Incubation Time:1 hour Result:Led to a reduced phosphorylation of SRp75, SRp55, and SRp20 compared with non TNF-α-stimulated controls.Led to a reduction of the TNF-α-induced increase in phosphorylation of all analyzed SR proteins compared with TNF-α-stimulated controls.

——

KH-CB-19

Cell Cycle/DNA Damage

CLK

CLK

Cancer

——

1354037-26-5

338.1886

C15H13Cl2N3O2

>98% (HPLC)

10 mM in DMSO

O=C(C(N1C)=C(/C(C#N)=C\N)C2=C1C(Cl)=C(Cl)C=C2)OCC

1H-Indole-2-carboxylic acid, 3-[(1E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-, ethyl ester

(-20℃)

With Ice Pack

≥ 2 years